Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

NCT ID: NCT05170334 Phase: PHASE2 Sponsor: H. Lee Moffitt Cancer Center and Research InstituteStatus: Active Not Recruiting

SUMMARY

This research study is investigating Binimetinib and Belinostat in participants with metastatic uveal melanoma. The research study will test the study drugs to see if the combination of binimetinib and belinostat can make tumors shrink or stop growing.

KEY ELIGIBILITY CRITERIA

- * Provision of signed and dated informed consent form.
- * Male or female, aged \>/= 18 years old
- * Life expectancy of greater than 3 months in the opinion of the investigator
- * Must have metastatic uveal melanoma, either initial presentation or recurrent, that is histologically diagnosed
- * Participant must have ECOG performance status of 0-1
- * Participant must have measurable disease, according to RECIST version 1.1
- * Participants must have normal organ and marrow function as defined below:
- * Leukocytes \>3,000/mcL
- * Absolute neutrophil count \>1,500/mcL
- * Platelets \>100,000/mcL

Total sites: 1 | 0 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT05170334) and public sources. Generated by FindMyCure.ai.